How Medicare’s New Drug Price Negotiation Program Could Expand Access to Selected Drugs

(By Juliette Cubanski, Anthony Damico, and Tricia Neuman for The Kaiser Family Foundation Published: Sep 26, 2023)

Medicare recently announced the first 10 Part D drugs selected for negotiation under Medicare’s new drug price negotiation program. These drugs were identified as the 10 top spending drugs covered under Medicare Part D without generic or biosimilar equivalents that have been on the market for at least seven years and also meet other selection criteria. The 10 drugs selected for the first round of negotiations include treatments for several medical conditions, including diabetes (Farxiga, Fiasp/NovoLog, Januvia, Jardiance), blood clots (Eliquis, Xarelto), heart failure (Entresto, Farxiga), psoriasis (Stelara, Enbrel), rheumatoid arthritis (Enbrel), Crohn’s disease (Stelara), and blood cancers (Imbruvica) (Appendix Table 1). Between June 2022 and May 2023, 8.3 million Medicare Part D enrollees used one or more of these medications. Negotiated prices for these 10 drugs will be available on January 1, 2026. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org